1 / 70

Introduction to HIV

Introduction to HIV. AIM. Epidemiology Testing for HIV infection Natural history of disease When to start ART (guidelines/trends in the field) Antiretroviral agents Common toxicities Opportunistic infections OI prophylaxis. Global summary of the AIDS epidemic, 2008.

sharne
Download Presentation

Introduction to HIV

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Introduction to HIV

  2. AIM • Epidemiology • Testing for HIV infection • Natural history of disease • When to start ART (guidelines/trends in the field) • Antiretroviral agents • Common toxicities • Opportunistic infections • OI prophylaxis

  3. Global summary of the AIDS epidemic, 2008 Total 33.4 million [31.1 – 35.8] Adults 31.3 million [29.2 – 33.7] Women (aged 15 and above) 15.7 million [14.2 – 17.2] Children under 15 years 2.1 million [1.2 – 2.9] Total 2.7 million [2.4 – 3.0]Adults 2.3 million [2.0 – 2.5]Children under 15 years 430 000 [240 K – 610K] Total 2.0 million [1.7 – 2.4]Adults 1.7 million [1.4 – 2.1]Children under 15 years 280 000 [150 K – 410 K] Number of people living with HIV in 2008 People newly infected with HIV in 2008 AIDS-related deaths in 2008

  4. Case • 23-year old woman presents to Emergency Department with one week history of fever, malaise, myalgias, headache and sore throat • Five days PTA she noted the onset of a new non-pruritic rash, on her face, torso, extremities • Two days PTA developed mouth sores that were so painful she was unable to eat or drink • PMH- negative • Soc Hx- sexually active, single, in grad school

  5. Case • Physical Examination in ED T 40oC. BP 104/76 P 108 R 20 Appears unwell HEENT: Multiple oral ulcerations Non-exudative pharyngitis Multiple cervical nodes (slightly tender) Diffuse maculopapular Rash

  6. Case • Laboratory data in ED • H/H 12/36 • WBC 3100 (65 segs, 25 lymphs, 6 atyp lymphs, 4 monos) • Platelets 71,000 • ALT 124, AST 75 • Urine drug screen negative • All other labs normal

  7. Differential Diagnosis • Infectious Mononucleosis • CMV • HIV • Enterovirus- Coxsackie • Adenovirus • Streptococcal pharyngitis • Arcanobacterium hemolyticum • Syphilis

  8. Principles of testing • HIV infected patients produce antibodies which recognize HIV proteins • ELISA • Western Blot • Immunofluorescence • Radioimmunoprecipitation

  9. Figure 6 Proteins Detected by HIV Western Blot rev tat pol 5’ 3’ IN PRO RT R U5 U3 R p24 p17 vif env gp120 env gp41 vpu nef vpr gag HIV-1 HIV-2 }gp160/120{ }gp135/120ENV{ p61POL p61POL p55GAG p55GAG p51POL p51POL gp41ENV gp36ENV p31POL p31POL p30GAG p24GAG p18GAG p17GAG

  10. Interpretation of Western Blot • Positive: ANY Two: p24, gp41, gp160/120 • Negative: NO positive bands • Indeterminate: the remainder • Isolated p24 band most common indeterminate • Isolated gp160/120 band suspicious for early infection

  11. A 38 year old multiparous nurse is evaluated because of an abnormal ELISA for HIV when she attempted to donate blood. A follow up Western Blot analysis has an indeterminate result. The patient is asymptomatic. She and her husband have a monogamous relationship and neither have used illicit drugs. Patient has never received a blood transfusion, and reports a needle stick injury approximately 8 years ago from an HIV negative individual. Her physical examination is normal, her CD4 count is normal, but her plasma viral load is 82 copies/ml. Which of the following is the most appropriate management at this time? • Recheck the plasma viral load now • Recheck the HIV serologic study in 3 months and 6 months • Begin HAART • Begin HAART if her CD4 count drops to <350/µL

  12. WB Interpretation • Infections (HIV-2 , HTLV-I, schisto) • Neoplasms • Dialysis • Ethnicity-Africans • Thyroiditis • Elevated Bilirubin • Rheumatologic diseases • Multiple pregnancy • Immunization (Tetanus, HIV) • Nephrotic proteinuria (massive) • Error in laboratory • Window period • Common variable immunodeficiency • NOT Subtype • Newest assays should identify even O Indeterminate False Negative

  13. HIV Infection Profile rev tat pol 5’ 3’ IN PRO RT R U5 U3 R p24 p17 vif env gp120 env gp41 vpu nef vpr gag Anti-Env antibody Relative Level HIV RNA Detection limit P24 antigen Time Post-Infection

  14. Natural history of the disease • Seroconversion- Median time from exposure to antibody-63 days (4 -10 wks) • Clinical latent period • Average rate of decline of CD4 cells after 1 yr is 50 cells (range- 30-90)- correlated with the viral load • PGL • Early symptomatic HIV infection • AIDS

  15. HIV Transmission Factors • Stage of the disease • Viral load • STD • Genital lesions • Frequency of unprotected sex • Circumcision

  16. Case • A 35 year old asymptomatic male with a CD4 count of 325, viral load of 15,000 presents to the clinic for routine evaluation. Hepatitis testing reveals that the patient has a positive HBsAg, AST-80 and ALT of 85. Which of the following is the most appropriate ART regimen • Delay treatment till he is symptomatic • Begin azt/3tc/efv • Begin abc/3tc/efv • Begin tfv/ftc/efv

  17. Response To Therapy • Potency of antiretroviral therapy • Lower viral load • Higher CD4 count • Rapid reduction in plasma viral load in response to therapy • Approximately 70% achieve this goal and 80% of patients in clinical trial settings achieve this goal

  18. Indications to start ART CD4 BASED IRRESPECTIVE OF CD4 COUNT History of an AIDS defining illness HIV associated nephropathy Concomitant hep B with indications to initiate hep B treatment Pregnancy • ART is recommended for patients with CD4 counts between 350 and 500 • 50% of the panel members would start ART in patients with CD4 counts greater than 500

  19. Probability of AIDS/Death

  20. Life Cycle of HIV Furtado MR et al. NEJM 1999;340:1614-22.

  21. Life Cycle of HIV Maturation inhibitors Fusion Inhibitor CCR5 INHIBITORS PI NRTI NNRTI INTEGRASE INHIBITORS Furtado MR et al. NEJM 1999;340:1614-22.

  22. Current Antiretroviral Medications Fusion inhibitor • Enfurtivide Integrase inhibitor • Raltegravir CCR5 inhibitor • Maraviroc NRTI • Abacavir • Didanosine • Emtricitabine • Lamivudine • Stavudine • Zidovudine • Zalcitabine • Tenofovir NNRTI First • Delavirdine • Efavirenz • Nevirapine Second • Etravirine PI • Amprenavir • Fosamprenavir • Atazanavir • Indinavir • Lopinavir • Nelfinavir • Ritonavir • Saquinavir • soft gel • hard gel • Tipranavir • Darunavir

  23. Drugs in the pipeline • NNRTI inhibitors • Rilpivirine • Integrase inhibitors • Elvitegravir • CCR5 inhibitors • Vicriviroc • CXCR4 inhibitors • Maturation inhibitors • CD4 blockers

  24. Initial Treatment: Preferred Components NRTI NNRTI • Efavirenz • Tenofovir • Emtricitabine PI • Boosted Atazanavir • Boosted Darunavir INTEGRASE • Raltegravir

  25. Initial Treatment: Alternative Components NRTI NNRTI • Nevirapine • Abacavir • Zidovudine • Lamuvidine PI • Lopinavir/Ritonavir • Boosted Fosamprenavir • Boosted Saquinavir

  26. Drugs with activity against hepatitis B and HIV activity • Tenofovir • Emtricitabine • Lamuvidine • Entecavir

  27. NRTI • Toxicities • Bone marrow toxicity, macrocytic anemia, neutropeniaGI-nausea, vomiting-AZT • General-headache, insomnia, asthenia-AZT • Lactic acidosis-D4T>DDI>AZT>TFV/ABC • Pancreatitis-DDI& D4T • Peripheral neuropathy-DDI/D4T>AZT>TFV • Lipoatrophy/lipodystrophy-D4T • Myopathy (including cardiomyopathy)-AZT • Hyperlipidemia-D4T>AZT>TFV/ABC • Rapidly progressive ascending muscle weakness-D4T

  28. NRTI • Abacavir • Abacavir hypersensitivity reaction • Fever, Rash • HLA type association with abacavir hypersensitivity • CAD • Tenofovir • Fanconi syndrome • Renal insufficiency • Dosage adjustment for Crcl<50 • Bone abnormalities in monkeys and ?fetal risks • ? osteopenia

  29. Non-Nucleoside Reverse Transcriptase inhibitors (NNRTI) • Efavirenz • CNS toxicity • Rash • Teratogenicity • False positive cannabinoid reaction • Nevirapine • Hepatotoxicity • Highest risk in women whose CD4 count was greater than 250 at the time of NVP initiation (11.0% vs 0.9%) • Men with CD4 counts greater than 400 (6.3%vs 1.2%) • Rash, with reports of TEN and SJS

  30. Protease inhibitors • Metabolic toxicities • Hyperlipidemia/Hypertriglyceridemia-RTV • Hyperbilirubinemia-ATZ and IDV • Nephrolithiasis-IDV (a few case reports with ATZ) • Pyuria and Interstitial nephritis-IDV • Hyperglycemia-IDV and LPV/RTV • Diarrhea-LPV/RTV (cap)& NFV • CAD • Lipodystrophy • Drug drug interactions • Increased bleeding among hemophiliacs • PR interval prolongation-ATZ

  31. Life threatening toxicities • Abacavir hypersensitivity reaction • Lactic Acidosis with NRTI • Nevirapine related hepatotoxicity • Steven Johnson’s syndrome

  32. Fusion inhibitors • Injection site reaction almost universal • Hypersensitivity reaction <1%- do not rechallenge • Increased rate of bacterial pneumonia

  33. A 35 year old female with HIV infection presents to the office. She was diagnosed with PCP and at that time had a CD4 count of 92/µL, viral load-105,000 copies/ml. AZT/3TC/EFV was initiated and 6 months post therapy her CD4 count was 323/µL and her VL was ND. Approximately 1 year ago she started missing appointments and 4 months prior her VL was 878 copies/ml and today her CD4 count is 300/µL and her VL is 5375 copies/ml. She remains asymptomatic. Which of the following is the most appropriate management? • Continue the current regimen • Substitute Nevirapine for Efavirenz • Add Nevirapine to the current regimen • Order an HIV genotype resistance assay • Recommend a drug holiday until she becomes symptomatic.

  34. DHHS guidelines • Monitoring of therapy • Average gains- 50-150 cells/first year and 50- 100 cells/year (assuming viral control) thereafter until a set point is reached • Viral load suppression to below undetectable should be achieved in 16-24 weeks in an ARV naïve patient • A 1 log decline in viral load in 2-8 weeks • Viral suppression in 12-24 weeks

  35. Opportunistic Infections • Fever and Pulmonary infiltrate • CNS manifestations • Ophthalmologic manifestations • Diarrhea

  36. Fever and Pulmonary infiltrate • A 32 year old male presents to the clinic with a 2 week history of non-productive cough, worsening SOB and fever. The patient was recently diagnosed with HIV and his CD4 count is 150 cells/µL. • O/E- HR-100, RR-22, T-100, Pulse ox-85% RA. • RS- examination reveals a few scattered rales and rhonchi.

  37. Differential Diagnosis • PCP- the most commonly diagnosed OI in North America • M.tuberculosis • Community acquired pneumonia • C.neoformans • H.capsulatum • C.immitis • R.equi • Atypical Mycobacteria (M.kansasii) • HSV • CMV • KS • Malignancies

  38. Case • A 40 year female is bought in by her family. Over the past few weeks her family has noticed that she has been forgetful, lethargic and confused. The patient has a CD4 count of 35 and has not been on ART or prophylaxis. • Examination reveals a right sided hemiparesis and VII nerve palsy

  39. Differential Diagnosis By Presenting Symptoms, Exam Findings • Nonfocal • Cryptococcal meningitis • CMV encephalitis • AIDS dementia • Lymphomatous meningitis • Other (TB, fungal) • Focal • Toxoplasmosis • Lymphoma • PML • Cryptococcoma • VZV • Meningovascular • syphilis • Other (TB, fungal)

  40. Is This CNS Toxoplasmosis? • Factors that lessen the likelihood: • On TMP-SMX or other prophylaxis • CD4 count > 100/μl • Negative serologies • Solitary lesion on MRI (multiple and bilateral lesions more c/w toxo) • No contrast enhancement • No MRI improvement on 2-3 weeks of therapy • Uptake on SPECT

  41. Primary AIDS-Related CNS Lymphoma • Mean CD4 = 30/μl • EBV associated • RARE among HIV negative patients about 2% of AIDS patients • Evolution: 2-8 weeks • Survival after diagnosis is usually limited to months • PCR of CSF is usually positive for EBV

More Related